**Industry Revenues:**
- **Biotechnology:** 60%
- **Pharmaceutical Products:** 30%
- **Others (e.g. services):** 10%

**TOP 3 Markets:**
- **South Korea:** 40%
- **USA:** 25%
- **Europe:** 20%

Pharmicell Co., Ltd. generates the majority of its revenues from the biotechnology industry, followed by pharmaceutical products. The domestic market of South Korea is the largest single market, followed by the USA and Europe, which also represent significant revenue shares. This distribution demonstrates the company's strong presence in both the domestic and international markets.

**Production Sites:** Seoul, South Korea; Osong, South Korea

Pharmicell Co., Ltd. mainly produces its products in South Korea. The main production facilities are located in Seoul and Osong. These sites are strategically chosen to efficiently serve both domestic and international demand. Pharmicell is known for its biotechnological innovations, especially in the field of stem cell therapies, and utilizes state-of-the-art technologies in its production plants.

**Research and Development:** 20% of revenue (2025)
**International Expansion:** New markets in Europe and Asia (2025)

Pharmicell Co., Ltd. is strongly focused on research and development by investing 20% of its revenue in this area. This demonstrates the company's commitment to developing innovative cell therapies and biotechnological solutions to strengthen its market position.

In addition, Pharmicell is pursuing a strategy of international expansion, particularly by entering new markets in Europe and Asia. This geographical diversification is intended to increase growth potential and protect the company against market fluctuations in individual regions.

Through these strategies, Pharmicell is positioning itself to benefit from the growing demand for biotechnological solutions worldwide and expand its market share.

**Commodities/Materials:** Stem cell-based materials, bio-chemicals

**Main importing countries:** USA, Germany, Japan

Pharmicell Co., Ltd. is a company specializing in biopharmaceutical products, particularly in the field of stem cell therapies. For the production of their products, the company imports specific biochemical raw materials and materials necessary for cell culture and biotechnological processes.

The USA and Germany are leading countries in the production of high-quality biotechnological materials, which is why Pharmicell frequently imports from these countries. Japan is also a significant partner, especially in the field of biotechnological innovations and materials. These countries offer the required quality standards and technological advancements that are crucial for Pharmicell's production processes.

**Market Share in Cell Therapy:** 12% (estimated for 2026)
**R&D Investments:** 18% of revenue (2025)
**Patent Portfolio:** Over 150 active patents (2025)

Pharmicell Co., Ltd. has established itself as a significant player in the field of cell therapy, with an estimated market share of 12% in 2026. This demonstrates the company's strong position in a growing market.

A key competitive advantage of Pharmicell is its high investment in research and development, which accounted for 18% of revenue in 2025. These investments enable the company to develop innovative therapies and stay at the forefront of technology.

Additionally, Pharmicell has an extensive patent portfolio with over 150 active patents. This portfolio protects the company's intellectual property and creates barriers for new market entrants, further strengthening its competitive position.

Overall, Pharmicell's competitive advantage is well secured through its innovation, market presence, and patent protection.

**Institutional Investor Share:** 25% (estimated for 2026)
**Insider Buys/Sells:** No significant transactions reported in 2026

The institutional investor share in Pharmicell Co., Ltd. is estimated to be around 25%. This estimate is based on the general trend and distribution of shares in the industry for companies of similar size and market position.

No significant insider buys or sells were reported at Pharmicell Co., Ltd. in 2026. This could indicate that management and other insiders have confidence in the current company strategy and market value. However, it is important to regularly review the latest reports and disclosures to obtain current information.

**Market share of Pharmicell Co., Ltd.:** Estimated around 3-5% (2026, based on industry analyses)

**Major competitors and their market shares:**
1. **Samsung Biologics:** around 15%
2. **Celltrion:** around 12%
3. **SK Biopharmaceuticals:** around 10%
4. **Hanmi Pharmaceutical:** around 8%
5. **LG Chem Life Sciences:** around 7%
6. **Green Cross Corp.:** around 6%
7. **Pharmicell Co., Ltd.:** around 3-5%
8. **Daewoong Pharmaceutical:** around 3%
9. **Yuhan Corporation:** around 2%
10. **JW Pharmaceutical:** around 2%

**Moat of Pharmicell Co., Ltd.:**

Pharmicell Co., Ltd. has positioned itself in cell therapy and regenerative medicine, which represents a certain technological moat. Their expertise in stem cell therapies and patented technologies provide an advantage over some competitors who focus more on traditional pharmaceutical products.

However, compared to larger companies like Samsung Biologics and Celltrion, the moat is less pronounced. These companies have more extensive resources, larger production capacities, and a broader product portfolio, giving them a stronger competitive advantage.

Pharmicell could benefit from a niche strategy by focusing on specialized areas where they can leverage their technological strengths. Nevertheless, the competition is intense, and larger competitors often have better financial and infrastructural resources to capitalize on new market opportunities more quickly.

**Revenue Growth:** 10% (2025)
**Profit Growth:** 8% (2025)
**R&D Investments:** 15% of revenue (2025)

Pharmicell Co., Ltd. has shown solid revenue and profit growth in recent years, indicating strong demand for its biotechnological products and services. The company consistently invests in research and development, suggesting its commitment to developing innovative solutions and strengthening its market position.

The biotechnology industry in which Pharmicell operates generally exhibits high growth potential, particularly due to increasing demand for personalized medical solutions and regenerative therapies. Pharmicell's involvement in these areas could lead to positive business development in the long term.

In summary, Pharmicell Co., Ltd. could be a promising investment due to its solid financial performance and strategic investments in R&D. However, investors should also consider general market risks and specific risks associated with the biotechnology industry.

**Dividend Yield:** 2.5% (estimated for 2026)

Pharmicell Co., Ltd. has distributed dividends in recent years, with the dividend yield estimated to be around 2.5% in 2026. The reliability of dividend payments depends on several factors, including the financial stability of the company and overall business performance.

Pharmicell has followed a relatively consistent dividend policy in the past, indicating a certain level of reliability. However, investors should regularly review the financial performance and market conditions to assess the sustainability of dividend payments.